Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140035 | 0.86 | MASP2 (0.45) | MASP2HDAC1NAMPTNLN | |
| SCHEMBL3144705 | 0.86 | MASP2 (0.49) | MASP2HDAC1NAMPTNLN | |
| SCHEMBL3140051 | 0.86 | MASP2 (0.52) | MASP2HDAC1NAMPTNLN | |
| SCHEMBL3156487 | 0.85 | MASP2 (0.47) | MASP2HDAC1NAMPT | |
| SCHEMBL3146169 | 0.85 | MASP2 (0.48) | MASP2NAMPTNLNCARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL1902944 | 0.84 | MASP2 (0.48) | MASP2HDAC1NAMPTNLNCARM1 | |
| SCHEMBL3154431 | 0.84 | MASP2 (0.56) | MASP2HDAC1NAMPTNLN | |
| SCHEMBL1903909 | 0.83 | NAMPT (0.54) | MASP2NAMPTNLN | |
| SCHEMBL1903911 | 0.83 | NAMPT (0.54) | MASP2NAMPTNLN | |
| SCHEMBL1901471 | 0.82 | PDPK1 (0.47) | MASP2HDAC1NAMPTNLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MASP2 3039/4885HDAC1 1534/4885NAMPT 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.